LexDanaLexDanabeta
Inventor

PAUL E. FLEMING

Inventor
US

Overview

3→
Patents
2022–2026
Patent span
Human necessities
Primary field (CPC A)

Patents· 3 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations38%
C07DHeterocyclic compounds38%
A61KPreparations for medical, dental or toiletry purposes25%
PatentTitleYear
12,595,265Inhibitors of activin receptor-like kinase202611,634,422Inhibitors of activin receptor-like kinase202311,236,086Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase2022

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2022–2026Patents assigned to BLUEPRINT MEDICINES CORP (3)· patent assignee history
2022–2026Based in US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
BLUEPRINT MEDICINES CORP32022–2026
Locations
LocationPatentsSpan
US32022–2026